Venture Kick

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.

Procavea Biotech specializes in developing a drug delivery platform centered on non-viral protein cages. This innovative platform is tailored for veterinary professionals, aiming to streamline and improve the efficiency of veterinary practice management. By providing a comprehensive solution, Procavea Biotech enhances overall operational effectiveness, enabling veterinary services to be delivered more seamlessly and integrated. Through its advancements, the company seeks to elevate the quality of care in veterinary practices.

Orio Therapeutics is redefining regeneration by modifying therapeutic proteins to optimize distribution through controlled localization.

Gaia Technologies has invented an innovative method to upcycle agricultural sidestreams into bio-compounds and added-value ingredients. Through its novel approach, Gaia tackles the ever-increasing trend to substitute synthetic compounds by natural alternatives in the cosmetics, food and feed sector. At the same time, Gaia responds to the pressing needs of the primary sector to create new value streams and to reduce the environmental footprint. Gaia Tech builds on the results from the EIT Food project Phenoliva and aims to commercialize a portfolio of value-added products derived from olive pomace (e.g. antioxidants, biochar, activated carbon, biogas) obtained through a technology that, differently from competitors’ solutions, is cost-effective and highly scalable.

ASTRA Therapeutics is a medication development business that uses cutting-edge science and technology to discover new therapeutic treatment candidates for the full spectrum of parasite disorders.

metaLead Therapeutics is focused on developing a novel peptide medication aimed at transforming the treatment of metal-related diseases, particularly lead poisoning. The company’s innovative approach involves a peptide that selectively binds to lead ions while preserving essential metal ions. This specificity ensures the medication remains highly stable and effective, allowing for administration through both oral and intravenous routes. By targeting lead poisoning, metaLead Therapeutics aims to provide a significant improvement in detoxification methods for individuals affected by this condition worldwide.

Tandem Therapeutics develops peptide therapeutics that target and treat the extracellular matrix barrier.

Adularia is a microbial-based therapy for Colorectal cancer.

Aukera Therapeutics is a biotech company that develops novel therapeutics for patients suffering from mTOR protein-related diseases such as cancer and neurogenerative diseases. Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel.

Synature is an early-stage Swiss startup. The aim of Synature is to make biodiversity measurable to quantify the heartbeat of ecosystems. The startup based at the EPFL Innovation Park aims to achieve this goal by leveraging bioacoustics. This involves recording the sounds of nature and using AI and signal processing to analyse the gathered data. Synature has a holistic offering including automated and autonomous recorders that send audio recordings from the field, automated analysis of the gathered data and a dashboard that displays the data in an easy-to-understand way.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on endometriosis. The company aims to accelerate the journey toward effective cures by addressing significant healthcare needs and introducing novel solutions that enhance women's health. FimmCyte is dedicated to empowering women to take control of their health and tackle unmet medical needs associated with these conditions.

Suri BioTech is a biotechnology company focused on developing health-promoting bacterial strains aimed at alleviating bloating and intestinal discomfort. The company specializes in creating science-based probiotics, particularly for infant health, utilizing proprietary strains that reduce hydrogen gas production by intestinal microorganisms. This innovative approach has potential applications in various functional gastrointestinal disorders, including infant colic and lactose intolerance. By leveraging its biotech platform, Suri BioTech seeks to provide effective solutions for individuals suffering from gastrointestinal issues.

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are unlocking the potential of glycomics and metabolomics in disease biomarker discovery and for the development of safer nutritional and pharmaceutical products.

NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.

Reactive Illumination proposes an innovative green way to convert any organic waste (biowaste, tyres etc.) to mainly solid carbon and energy-efficient gases like H2, CH4, etc. within seconds without any chemicals that can be collected and used.

inSEIT provides an integral service for enzyme immobilization, from the matching between enzymes and supports to the application and process scale-up.

Adularia is a microbial-based therapy for Colorectal cancer.

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and nanofluidics.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

Oncobit is focused on enhancing personalized cancer care through the development of precise and highly sensitive diagnostic and monitoring tests. The company combines technical expertise with proprietary software and engages in close clinical collaborations, initially concentrating on melanoma while maintaining the potential to expand its solutions to other cancer types. Oncobit's innovative approach aims to improve patient outcomes by providing comprehensive and sensitive tests that enable clinics to offer tailored therapies and diagnostics, ensuring that cancer monitoring keeps pace with advancements in treatment methodologies.

Bottneuro specializes in developing non-invasive therapies for patients with early to moderate-stage Alzheimer's Disease. The company utilizes its NENI technology platform to create stimulation protocols that employ electrical stimulation of neurons and glial cells in the brain. Additionally, Bottneuro's innovative brain therapy system incorporates plant-based components and features a 3D-printed cap designed for continuous monitoring and targeted delivery of active substances. This approach aims to address the specific needs of Alzheimer's patients, ultimately enhancing their quality of life and improving treatment outcomes.

CompagOs is focused on enhancing cancer treatment for patients with bone cancer through an innovative in vitro diagnostic tool. Utilizing advanced 3D bioprinting technology, the company creates mineralized bone organoids that replicate the unique cancerous conditions of individual patients within a controlled laboratory environment. This allows for the assessment of drug reactions in a complex bone microenvironment, surpassing the limitations of traditional animal and 2D models. The platform not only aims to personalize treatment options for patients but also serves as a valuable research tool for clinical, pharmaceutical, and biotech sectors. By enabling researchers to evaluate drug efficacy in a realistic and patient-relevant context, CompagOs is positioned to drive advancements in oncology and improve patient outcomes.

ArcoScreen is a Swiss medtech is developing a new microfluidic discovery platform for drug screening targeting cell membrane receptors.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

Abologix is a biopharmaceutical company focused on developing innovative therapies for oncology. The company specializes in creating monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. This treatment aims to provide options for patients who do not respond to conventional cancer therapies, addressing various oncological conditions. By advancing its research in this area, Abologix seeks to enhance treatment outcomes and improve the quality of care for cancer patients.

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinical devices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

Bionomous specializes in the development of a biotechnological device that automates the observation, analysis, and sorting of small biological entities. By integrating innovative micro-engineering design with machine learning techniques, Bionomous has created a system that facilitates the automatic inspection and sorting of miniature biological entities. This technology is particularly valuable for studies in genetics, development, behavioral biology, and toxicology, allowing biotech companies to streamline processes related to the visual inspection, sorting, and dispensing of these entities.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Abologix is a biopharmaceutical company focused on developing innovative therapies for oncology. The company specializes in creating monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. This treatment aims to provide options for patients who do not respond to conventional cancer therapies, addressing various oncological conditions. By advancing its research in this area, Abologix seeks to enhance treatment outcomes and improve the quality of care for cancer patients.

LifeMatrix specializes in the development of biomimetic implants and bio-engineering technology aimed at treating cardiovascular diseases and facilitating the growth of human replacement tissues. The company creates human cell-derived, off-the-shelf tissue-engineered implants that transform into living tissue after implantation, allowing them to grow and regenerate alongside the patient. This innovative technology addresses the limitations of traditional implants and is designed to enhance patient recovery. LifeMatrix's award-winning solutions are founded on over 20 years of extensive research, supported by multiple national and international grants, and validated through more than 100 peer-reviewed publications. Preclinical studies have demonstrated the safety and efficacy of these implants, paving the way for their clinical application.

Bionomous specializes in the development of a biotechnological device that automates the observation, analysis, and sorting of small biological entities. By integrating innovative micro-engineering design with machine learning techniques, Bionomous has created a system that facilitates the automatic inspection and sorting of miniature biological entities. This technology is particularly valuable for studies in genetics, development, behavioral biology, and toxicology, allowing biotech companies to streamline processes related to the visual inspection, sorting, and dispensing of these entities.

Nutrix is a Swiss health-tech company founded in 2019 and based in Basel. It specializes in developing a nanosensor that is placed on the tooth to measure glucose levels in saliva, providing a non-invasive method for users to monitor their health. This technology is integrated with an external application that tracks food intake and offers dietary advice, aiming to aid in the prevention of diabetes. Nutrix combines artificial intelligence with wearables to create cost-effective healthcare solutions. In 2025, the company plans to introduce CortiSense, a non-invasive cortisol monitoring sensor that has already received a CES Innovation Award, further expanding its portfolio of health monitoring technologies. Through its innovative approach, Nutrix enables users to manage their health conditions effectively without the need for frequent medical consultations.

Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.

MimiX Biotherapeutics Sàrl, established in 2016 and based in La Tène, Switzerland, specializes in the development of biofabrication technology for therapeutic and diagnostic applications. The company focuses on creating an ultra-fast biomanufacturing process that enables the production of patient-specific biological tissue equivalents. This innovative approach supports regenerative medicine and personalized healthcare, allowing for tailored treatments that meet individual patient needs. By advancing tissue engineering techniques, MimiX Biotherapeutics aims to enhance the precision and effectiveness of medical interventions.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

OptiChroniX is a Swiss digital health solution company focused on enhancing brain health through early intervention. The company develops digital health interventions that combine biomedical, behavioral, computing, and engineering research, which are accessible via smartphones. These interventions allow patients to personalize and monitor their brain health by integrating data from various wearables. By offering tailored coaching, OptiChroniX aims to improve health literacy and medication adherence, addressing modifiable risk factors linked to cognitive decline, particularly in patients with Alzheimer’s disease and related co-morbidities. The company's mission is to optimize lifestyle choices and make healthcare more effective, ultimately enhancing clinical outcomes and quality of life.

Terapet was founded at CERN by two physicists – Christina Vallgren and Marcus Palm – along with Professor Raymond Miralbell from the Geneva University Hospitals (HUG). They have already proven the feasibility of their concept and are now developing an initial version for market launch.

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the nervous system. Neural implants are medical devices made of electrodes that can record or stimulate the brain, spinal cord, or peripheral nerves to monitor or treat patients suffering from neurological disorders. However, current clinical devices are too stiff compared to the soft tissues of the body, which limits benefits for patients. At Neurosoft Bioelectronics, we have developed a new generation of soft and conformable implantable electrodes that seamlessly interface with the nervous tissues and can improve clinical outcomes for patients.

deepCDR Biologics AG is a biotechnology company based in Basel, Switzerland, founded in 2018. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on the development of innovative biologics, deepCDR Biologics aims to enhance the effectiveness of therapeutic antibodies in the pharmaceutical industry.

Swiss Medical Union SA, founded in 2019 and based in Yverdon-les-Bains, Switzerland, specializes in healthcare technology focused on testing the interaction, efficiency, and safety of new medical products. The company manufactures Micro-Bioreactor equipment that allows for ex vivo testing with human organ and tissue models, enabling the selection of appropriate therapies tailored to individual patient needs. Additionally, Swiss Medical Union develops software that simulates organ activity, analyzes interactions between medical products and specific organs, and monitors real-time effects of treatments within the circulatory system. The company also provides clinical testing services aimed at supporting healthcare professionals in making informed clinical decisions, particularly in cancer treatment. Its offerings are designed to enhance therapeutic outcomes while minimizing the risks associated with unnecessary treatments.

deepCDR Biologics AG is a biotechnology company based in Basel, Switzerland, founded in 2018. The company specializes in antibody optimization and discovery services, utilizing advanced technologies to deliver scalable solutions for its clients. By focusing on the development of innovative biologics, deepCDR Biologics aims to enhance the effectiveness of therapeutic antibodies in the pharmaceutical industry.

Autonomyo enables people with neurological gait disorders to walk again and win back freedom of movement. Autonomyo is a committed team of engineers, developers, and healthcare professionals dedicated to improving the lives of people with gait impairment.

Galventa is a company focused on enhancing sleep quality and wakefulness through the development of innovative galenic platform technologies. It produces a food supplement that utilizes micro-pellets designed for time-controlled release, specifically aimed at alleviating symptoms of sleep inertia. This product helps regulate the sleep-wake cycle and supports the synchronization of the circadian clock, enabling individuals who experience sleep inertia to align their sleep patterns with their daily activities. Through clinically tested solutions, Galventa addresses the challenges associated with sleep disruption, promoting better overall sleep health.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

MaxWell Biosystems AG is an electronics and biotechnology company based in Zurich, Switzerland, dedicated to advancing neuroscience research and enhancing preclinical drug discovery. Founded in 2016, the company specializes in functional cell imaging platforms, most notably its MaxOne electrophysiology platform. This innovative system features a high-density microelectrode array with 26,400 electrodes and 1,024 low-noise readout channels, which allows for precise recording and stimulation of electrogenic cells in vitro. By enabling researchers to extract detailed single cell and network parameters, MaxWell's technology significantly accelerates the characterization of cellular functions, reducing the typical timeframe from several months to just a few weeks. This advancement aids in phenotypic screening as well as drug toxicity and efficacy testing.

Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.

Bloom Biorenewables Ltd is a Swiss company founded in 2019, focused on developing technology that transforms wood and agricultural waste into renewable materials as alternatives to petroleum. The company specializes in creating bio-based materials for the chemical industry, targeting various markets including fragrances, plastics, and textiles. By introducing innovative production methods for biorenewable products and fuels, Bloom Biorenewables aims to provide sustainable solutions that reduce reliance on fossil fuels and contribute to climate change mitigation.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

Alibion AG, founded in 2018 and based in Allschwil, Switzerland, specializes in drug discovery and the development of therapeutics. The company addresses the challenge of bringing innovative therapies from academic laboratories to patients by accelerating early-stage development. Alibion focuses on identifying promising new therapeutics and collaborates with outsourced partners to streamline the development process, thereby minimizing time and costs while ensuring compliance with quality standards. By doing so, Alibion aims to enhance the availability of novel treatments, ultimately improving patient outcomes on a global scale.

Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.

Mitoscreening platform (MSP) is used to screen metabolism-targeting anti-cancer drugs to discover.

Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.

Prolongate is a protein drugs and biotech company.

ALAnostics is a biopharmaceutical company that specializes in oncodiagnostics, originating as a spin-off from the University of Geneva. The company focuses on developing innovative tumour painting technology designed to assist surgeons in the real-time identification and removal of breast cancer during surgery. By utilizing nanomedicines for fluorescence-guided surgery, along with 5-ALA prodrugs for photodynamic therapy and light-activated antimicrobials, ALAnostics aims to enhance the accuracy of tumor removal, ultimately improving patient outcomes and saving lives.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

BIOMEM

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes microscopic worms for substance testing in pharmaceutical, chemical, and cosmetic industries. Their flagship product, the Caenorhabditis elegans-on-chip, integrates the use of these organisms for in vivo testing with a fully automated platform for in vitro culture, treatment, and analysis. This technology facilitates comprehensive toxicity testing, drug discovery, and anthelmintic testing applications, allowing clients to evaluate biological responses observable only at the whole-organism level. Nagi Bioscience aims to transform traditional testing methodologies by introducing its unique "Organism-on-Chip" technology.

Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.

Hemolytics is a MedTech company focused on advancing malaria detection through the development of a medical diagnostic device. This innovative device utilizes a chemical amplification method to enhance the sensitivity of malaria detection, achieving a level ten times greater than existing malaria rapid diagnostic tests. By amplifying a pan-malarial biomarker with stable and inexpensive reagents, Hemolytics aims to provide a point of care test that allows for the early detection of malaria, ultimately improving patient outcomes and facilitating timely treatment.

SEED Biosciences are a Swiss award-winning startup providing innovative solutions for your single cell assays.

MOMM Diagnostics is a Swiss company founded in 2018 and headquartered in Basel. It specializes in the development of an in-vitro diagnostic test aimed at the early diagnosis of preeclampsia, a serious condition that can affect pregnant women. The company's innovative diagnostic device is designed for use at the point of care, allowing for quicker diagnosis and intervention, thereby improving patient outcomes. By focusing on women's health, MOMM Diagnostics aims to provide essential support to healthcare providers and enhance the care of pregnant women experiencing potential complications.

Limula is a company that has developed an innovative platform technology designed to enhance the scalability of cell therapy production. By integrating a bioreactor and a centrifuge into a single device, Limula's solution enables healthcare providers to manufacture cell and gene therapies in a decentralized manner, bringing these treatments closer to patients. This platform, which includes hardware, software, and consumables, aims to make highly personalized and curative therapies more accessible. The automation of the production process not only increases safety and reproducibility but also allows for the large-scale manufacturing of cell therapy products, thereby addressing the critical need for improved access to gene-engineered therapies.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes microscopic worms for substance testing in pharmaceutical, chemical, and cosmetic industries. Their flagship product, the Caenorhabditis elegans-on-chip, integrates the use of these organisms for in vivo testing with a fully automated platform for in vitro culture, treatment, and analysis. This technology facilitates comprehensive toxicity testing, drug discovery, and anthelmintic testing applications, allowing clients to evaluate biological responses observable only at the whole-organism level. Nagi Bioscience aims to transform traditional testing methodologies by introducing its unique "Organism-on-Chip" technology.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Equsave is a livestock breeding management company located in Schlieren, Switzerland. It specializes in the development of an animal-free, sustainable alternative to traditional pregnant mare serum gonadotropin (PMSG), a hormone commonly used in livestock breeding. By providing a product that eliminates the need for horse blood, Equsave enables horse breeders to manage breeding practices in a more ethical and environmentally friendly manner. The company's innovative approach aims to improve the efficiency of livestock breeding while adhering to sustainable practices.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

SEED Biosciences are a Swiss award-winning startup providing innovative solutions for your single cell assays.

ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in the development of non-invasive assays aimed at the screening, diagnosis, and monitoring of cancer. The company's initial product is a urine assay designed specifically for the screening of prostate cancer, reflecting its commitment to advancing cancer detection methods. Through its innovative approaches, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.

Viventis Microscopy is focused on developing an innovative light sheet microscope system designed for long-term live imaging of light-sensitive samples. This system includes both specialized hardware and custom microscope control software, allowing researchers to conduct extended imaging of delicate specimens such as embryos and organoids. By facilitating detailed observation of these samples, Viventis Microscopy aims to support researchers and organizations in accelerating drug development processes.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes microscopic worms for substance testing in pharmaceutical, chemical, and cosmetic industries. Their flagship product, the Caenorhabditis elegans-on-chip, integrates the use of these organisms for in vivo testing with a fully automated platform for in vitro culture, treatment, and analysis. This technology facilitates comprehensive toxicity testing, drug discovery, and anthelmintic testing applications, allowing clients to evaluate biological responses observable only at the whole-organism level. Nagi Bioscience aims to transform traditional testing methodologies by introducing its unique "Organism-on-Chip" technology.

EraCal Therapeutics AG is a Swiss biotech company founded in 2018 and located in Schlieren, Switzerland. The company specializes in drug discovery aimed at treating various diseases, particularly focusing on obesity and its associated comorbidities. EraCal develops an innovative in-vivo screening platform that identifies appetite suppressors that selectively target food intake without causing neuronal side effects. This platform enables the creation of drugs that significantly outperform existing anti-obesity agents in both potency and selectivity, allowing patients to effectively suppress appetite and achieve weight loss.

Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.

Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.

Rapid Graft develops a novel dermatome to easily take small split-skin grafts to improve treatment of chronic wound patients and to cover future needs in tissue engineering. Rapid Graft is headquartered in Zurich, Switzerland.

Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.

SEED Biosciences are a Swiss award-winning startup providing innovative solutions for your single cell assays.

REM Analytics accurately addresses the Microtype of people for the microbiome industry. The company provides this measurement as an analytical service allowing customers to improve the impact of their products. The company has the unique capability to measure the colonization of specific probiotic strain in the microbiome of people. It can also measure the effectiveness of these strains on the micro type at large, as well as differences induced by changes in food and lifestyle. The company's objective is to allow the development of Evidence-based, personalized microbiome-based treatments.

ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

INOFEA AG is a biotech company that offers a platform technology capable to fit enzymes in vivo and process conditions. The company was founded in 2014 and is headquartered in Basel, Switzerland.

UniteLabs, AG is a software company based in Basel, Switzerland, founded in 2017, that specializes in automation solutions for life science research facilities. The company offers an infrastructure platform that integrates hardware and software across various vendors, enabling the digitalization of life science research and development. Its solutions include a plug-and-play robotic lab assistant, on-demand automation, and control software, which help improve the quality and reproducibility of scientific work. By facilitating seamless connections between laboratory equipment, UniteLabs allows users to rapidly build and deploy custom workflows, enhancing lab efficiency and flexibility. The platform also features a growing library of connectors and software development kits for API access, aimed at transforming laboratory operations and accelerating scientific throughput.